ColoSpan and the EIC Accelerator: Avoiding the Stoma, Sold to Galmed

29 September 20261,077 words6 min

After rectal cancer surgery, surgeons often create a temporary stoma, diverting the bowel through the abdomen into a bag, to protect the join from leaking. ColoSpan, an Israeli company based in Kfar Saba, developed CG-100, a "temporary intraluminal bypass device" placed inside the bowel to protect the join, aiming to spare patients the stoma.

The European Innovation Council granted €2,269,312 towards a €3.24 million project, part of what the company announced as €8.2 million of EIC support in 2021. The project supported preparation of the US pivotal trial and retained the device's EU certification, according to CORDIS. ClinicalTrials.gov listed the trial as recruiting in its 6 July 2026 update. On 22 June 2026 Galmed Pharmaceuticals completed its acquisition of ColoSpan. Under the amended agreement filed with the SEC, Galmed paid $3.3 million in cash at closing; up to $2 million in additional earn-outs is contingent on future sales and specified events.

€2.27MEIC grant, 70% of a €3.24M project
€8.2MTotal EIC support announced, 2021
250Patients planned in the pivotal trial
$3.3MCash Galmed paid at closing

Company file

Legal entity
ColoSpan Ltd., Kfar Saba, Israel
Founder
Boaz Assaf
Product
CG-100 intraluminal bypass device
Regulatory
CE marked under the EU MDR; FDA Breakthrough Device Designation; US investigational use
Pivotal trial
NCT04184973, recruiting since 2020, 250 planned
Owner
EoCene Ltd. (formerly Galmed Pharmaceuticals), since 22 June 2026
EIC project
CG-100, 1 Jun 2022 to 31 May 2025
EIC funding
Blended finance

Where ColoSpan Stands Today

ColoSpan is a wholly owned subsidiary of EoCene Ltd. (formerly Galmed Pharmaceuticals), which completed the acquisition on 22 June 2026. In September 2026, EoCene described ColoSpan as a "commercial-stage medical device company" and CG-100 as commercial-ready in Europe and Israel. Those are company descriptions; they do not establish sales volume or broad commercial adoption. At the time of the deal announcement, Galmed said it contemplated investing $6 million and planned a second-half 2026 soft launch, initially in Germany, Austria and Switzerland. This was a forward-looking plan. The amended agreement replaced $2 million of Galmed shares with $800,000 more cash and added earn-outs on sales from July 2027, with no payment on the first $5 million of cumulative sales.

The exit

Acquisition terms and earlier funding figures

The acquisition closed on 22 June 2026. The $3.3M cash was paid at closing; up to $2M additional earn-out is contingent on future sales and certain events. Amounts in different currencies are not converted.

Galmed Form 6-K, June 2026; ColoSpan announcements. Amounts in millions; currencies not converted.

The Technology: A Bypass Inside the Bowel

In a 60-patient study reported in 2017, ColoSpan said the device was inserted and removed in all patients and the leak rate was 5%, against an expected 10 to 12%. A newer randomised pivotal trial on ClinicalTrials.gov started in June 2020, plans 250 patients and expects primary completion at the end of 2026.

"This is an additional endorsement and a vote of confidence in Colospan's team, our novel technology."

Boaz Assaf, CEO and founder, ColoSpan, December 2021

What the EIC Project Promised, and What CORDIS Shows

The EIC project

EU contribution to a EUR 3.24M project

CORDIS lists EUR 2,269,312 as the EU contribution and EUR 972,563 as other project costs. The balance is not necessarily ColoSpan?s own cash contribution. The company separately announced EUR 8.2M in EIC support without splitting grant and equity.

CORDIS project 190124297. Values in EUR millions.

The project promised a device "designed to reduce the rate of diverting stoma and its related complication by at least 70%". The CORDIS report describes evaluating 35 sites in the US and EU and initiating 15 for the pivotal trial, retaining the MDR certificate for both device sizes, and manufacturing and regulatory work. It reports no enrolment figures or results, and projects savings of more than €19,000 per patient.

  1. EU certification keptDeliveredMDR certificate retained.
  2. Pivotal trial sitesDelivered15 sites initiated.
  3. Pivotal trial resultsPendingStill recruiting in 2026.
  4. 70% fewer stomas shownNot shownNo comparative data yet.

What Has Happened Since the Award

The record

A pivotal trial recruiting since 2020, then acquired in 2026

ClinicalTrials.gov showed the US pivotal trial as recruiting in its 6 July 2026 update. Galmed completed the acquisition on 22 June 2026; Galmed changed its name to EoCene in September. The maximum earn-out is contingent, not cash paid at closing.

  1. 2017First study60 patients; 5% leak rate; $7.7M raised
  2. Jun 2020Pivotal trial startsRandomised CG-100 trial, 250 patients planned
  3. Dec 2021EIC awardCompany announces €8.2M from the EIC
  4. Jun 2022EIC project startsPivotal trial sites, manufacturing, EU market€2.27M grant
  5. May 2025EIC project ends15 trial sites initiated; MDR certificate retained
  6. Jun 2026Galmed dealShare purchase agreed and amended to all cash; acquisition completed 22 June
  7. Jun 2026AcquiredColoSpan became wholly owned subsidiary of Galmed (now EoCene)$3.3M cash + contingent earn-out

CORDIS; ClinicalTrials.gov; Galmed/EoCene SEC filings.

The Money

ColoSpan announced €8.2 million of EIC support in December 2021 without splitting grant and equity; CORDIS records the grant at €2.27 million. In 2017 it had raised $7.7 million led by Triventures. The sale to Galmed values the company at $3.3 million in cash plus up to $2 million more if sales reach set levels. Whether the EIC held equity, and what it received, is not public.

What cannot be checked

Whether the EIC Fund invested and what it got from the sale, how many patients the pivotal trial has enrolled and when it will report are not public.

Why Europe Should Care

A device that could spare some patients a stoma may improve quality of life; whether CG-100 achieves the project's target reduction remains to be established in the pivotal trial. CORDIS reports projected savings of more than EUR 19,000 per patient, a company estimate rather than an observed outcome. The EIC project supported trial preparation and certification retention; the pivotal trial began in 2020, before the project began. In 2026 ColoSpan was acquired by Galmed, now EoCene, for $3.3 million in cash plus up to $2 million in contingent earn-outs.

What the project promised

A bypass device to cut diverting stomas and their complications by at least 70%.

What the record shows

A CE-marked device, a pivotal trial listed as recruiting in July 2026, and an acquisition by Galmed, now EoCene, for $3.3M cash plus contingent earn-outs.

The Verdict

Kept alive, then sold

CORDIS reports that the EIC project retained the MDR certificate and initiated 15 trial sites; the pivotal study began in 2020, before this project started. As of the latest registry update located (June 2026), it was recruiting, so its pivotal results had not yet established whether CG-100 reduces stoma creation by the project?s targeted 70%. Galmed completed the acquisition on 22 June 2026 for $3.3 million cash, with up to $2 million in contingent earn-outs.

ColoSpan and EoCene have not been asked for comment for this article. It is based entirely on company statements, SEC filings, EU project data and the trial registry, linked throughout.

Industry

HealthMedical devices

Focus
  • Gastrointestinal devices
Technologies
  • Implantable devices
Keywords
  • Colorectal surgery
  • Stoma avoidance
  • Rectal cancer
  • Anastomotic leak